TCI Wealth Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

TCI Wealth Advisors’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-180	Closed	-$4.39K	–	2396
2023 Q1	$4.39K	Buy	180 +113	+169%	+$3.32K	﹤0.01%	1618
2022 Q4	$2.11K	Buy	+67	New	+$1.89K	﹤0.01%	1962
2022 Q2	–	Sell	-149	Closed	-$5K	–	2579
2022 Q1	$5K	Buy	+149	New	+$4.35K	﹤0.01%	1628
2021 Q4	–	Sell	-104	Closed	-$3K	–	2571
2021 Q3	$3K	Buy	+104	New	+$2.92K	﹤0.01%	2053

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

TCI Wealth Advisors's CERE Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2023, closing a stake of 180 shares — an estimated $4.39K sold.

TCI Wealth Advisors first reported a position in CERE in Q3 2021 and held it in 4 quarters. The position peaked at $5K in Q1 2022. 125 funds tracked by Wall St. Rank hold CERE as of Q2 2023.

TCI Wealth Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 180 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2023, an estimated $4.39K.
TCI Wealth Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
TCI Wealth Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $5K in Q1 2022.
125 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.